共 50 条
- [1] S1616: Ipilimumab plus nivolumab versus ipilimumab alone in patients with metastatic or unresectable melanoma that did not respond to anti-PD-1 therapy.CANCER RESEARCH, 2022, 82 (12)Vanderwalde, Ari M.Moon, JamesKendra, KariKhushalani, Nikhil I.Collichio, FrancesSosman, Jeffrey A.Ikeguchi, AlexandraVictor, Adrienne I.Truong, Thach-GiaoChmielowski, BartoszPortnoy, David C.Wu, Michael C.Grossmann, Kenneth F.Ribas, Antoni
- [2] Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanomaLANCET ONCOLOGY, 2021, 22 (08): : E342 - E342Li, Mengqian
- [3] Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma replyLANCET ONCOLOGY, 2021, 22 (08): : E343 - E344da Silva, Ines PiresAhmed, TasniaReijers, Irene L. M.Warner, Allison BetofPatrinely, James RandallSerra-Bellver, PatricioAllayous, ClaraMangana, JoannaZimmer, LisaTrojaniello, ClaudiaKlein, OliverGerard, Camille L.Michielin, OlivierHaydon, AndrewAscierto, Paolo A.Carlino, Matteo S.Lebbe, CelesteLorigan, PaulJohnson, Douglas B.Sandhu, ShahneenLo, Serigne N.Menzies, Alexander M.Long, Georgina, V
- [4] Cost-Effectiveness of Ipilimumab Plus Anti-PD-1 Therapy Versus Ipilimumab Alone in Patients With Metastatic Melanoma Resistant to Anti-PD-(L)1 MonotherapyFRONTIERS IN ONCOLOGY, 2021, 11Peng, YeZeng, XiaohuiPeng, LiubaoLiu, QiaoYi, LidanLuo, XiaLi, SiniWang, LitingQin, ShuxiaWan, XiaominTan, Chongqing
- [5] Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced MelanomaJOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (02) : 127 - +Wolchok, Jedd D.Chiarion-Sileni, VannaGonzalez, ReneGrob, Jean-JacquesRutkowski, PiotrLao, Christopher D.Cowey, C. LanceSchadendorf, DirkWagstaff, JohnDummer, ReinhardFerrucci, Pier FrancescoSmylie, MichaelButler, Marcus O.Hill, AndrewMarquez-Rodas, IvanHaanen, John B. A. G.Guidoboni, MassimoMaio, MicheleSchoffski, PatrickCarlino, Matteo S.Lebbe, CelesteMcArthur, GrantAscierto, Paolo A.Daniels, Gregory A.Long, Georgina, VBas, TubaRitchings, CoreyLarkin, JamesHodi, F. Stephen
- [6] Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanomaEUROPEAN JOURNAL OF CANCER, 2017, 75 : 47 - 55Zimmer, LisaApuri, SusmithaEroglu, ZeynepKottschade, Lisa A.Forschner, AndreaGutzmer, RalfSchlaak, MaxHeinzerling, LucieKrackhardt, Angela M.Loquai, CarmenMarkovic, Svetomir N.Joseph, Richard W.Markey, KellyUtikal, Jochen S.Weishaupt, CarstenGoldinger, Simone M.Sondak, Vernon K.Zager, Jonathan S.Schadendorf, DirkKhushalani, Nikhil I.
- [7] CD8 T cell-melanoma cell interactions in response and resistance to ipilimumab plus nivolumab: Biopsy analysis of SWOG S1616CANCER RESEARCH, 2023, 83 (07)Campbell, Katie M.Kuklinski, LawrenceBustami, ZaidMaxey, JessicaMedina, EgmidioSantulli-Marotto, SandraGonzalez, Cynthia R.Aldeen, Nataly NaserKendra, KariPatel, SapnaHu-Lieskovan, SiwenMoon, JamesBellasea, ShaySpencer, Christine N.Thompson, Marshall A.Wu, MichaelVanderwalde, AriScumpia, Philip O.Ribas, Antoni
- [8] Combining ipilimumab (ipi) and nivolumab (nivo) in advanced melanoma following progression on a PD-1 inhibitor (SWOG S1616)JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Vanderwalde, Ari M.Latkovic-Taber, MichaellaHu-Lieskovan, SiwenGrossmann, Kenneth F.Sosman, Jeffrey AlanCampos, DanaeWu, MichaelRibas, Antoni
- [9] Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanomaJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (07)Bhave, PrachiAhmed, TasniaLo, Serigne N.Shoushtari, AlexanderZaremba, AnneVersluis, Judith M.Mangana, JoannaWeichenthal, MichaelSi, LuLesimple, ThierryRobert, CarolineTrojanello, ClaudiaWicky, AlexandreHeywood, RichardTran, LenaBatty, KathleenDimitriou, FlorentiaStansfeld, AnnaAllayous, ClaraSchwarze, Julia K.Mooradian, Meghan J.Klein, OliverMehmi, InderjitRoberts-Thomson, RachelMaurichi, AndreaYeoh, Hui-LingKhattak, AdnanZimmer, LisaBlank, Christian U.Ramelyte, EgleKaehler, Katharina C.Roy, SeverineAscierto, Paolo A.Michielin, OlivierLorigan, Paul C.Johnson, Douglas B.Plummer, RuthLebbe, CelesteNeyns, BartSullivan, RyanHamid, OmidSantinami, MarioMcArthur, Grant A.Haydon, Andrew M.Long, Georgina, VMenzies, Alexander M.Carlino, Matteo S.
- [10] Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort studyLANCET ONCOLOGY, 2021, 22 (06): : 848 - 857Stratigos, Alexander J.Sekulic, AleksandarPeris, KettyBechter, OliverPrey, SorillaKaatz, MartinLewis, Karl D.Basset-Seguin, NicoleChang, Anne Lynn S.Dalle, StephaneOrland, Almudena FernandezLicitra, LisaRobert, CarolineUlrich, ClaasHauschild, AxelMigden, Michael R.Dummer, ReinhardLi, SiyuYoo, Suk-YoungMohan, KosalaiCoates, EbonyJankovic, VladimirFiaschi, NathalieOkoye, EmmanuelBassukas, Ioannis D.Loquai, CarmenDe Giorgi, VincenzoEroglu, ZeynepGutzmer, RalfUlrich, JensPuig, SusanaSeebach, FrankThurston, GavinWeinreich, David M.Yancopoulos, George D.Lowy, IsraelBowler, TimothyFury, Matthew G.